![ChemWerth Lanreotide Acetate](https://www.pharmacompass.com/image/flap/chemwerth-lanreotide-acetate-desktop-headergif-34152.gif)
![ChemWerth Lanreotide Acetate](https://www.pharmacompass.com/image/flap/chemwerth-lanreotide-acetate-mobgif-40411.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://endpts.com/fda-denies-ipsens-citizen-petition-for-blockbuster-drug-somatuline/
https://www.indianpharmapost.com/drug-approval/cipla-receives-final-approval-for-the-generic-version-of-somatuline-depot-injection-15676
https://economictimes.indiatimes.com/industry/healthcare/biotech/cipla-gets-usfda-nod-to-market-lanreotide-injection/articleshow/110326237.cms
https://endpts.com/dc-district-court-sides-with-fda-after-ipsen-sued-over-blockbusters-classification-as-a-drug/
https://www.globenewswire.com//news-release/2022/12/05/2567225/0/en/European-Commission-approves-Mycapssa-for-the-treatment-of-Acromegaly.html
https://www.business-standard.com/article/news-cm/cipla-gets-usfda-nod-for-lanreotide-injection-121122000166_1.html
https://www.expresspharma.in/cipla-receives-usfda-nod-to-market-lanreotide-injection-in-us-market/
https://www.biospace.com/article/releases/esmo-2020-phase-ii-clarinet-forte-results-show-increasing-dose-frequencies-of-somatuline-autogel-lanreotide-allows-patients-with-nets-to-delay-treatment-escalation-by-up-to-8-3-months/
https://www.biospace.com/article/releases/esmo-2020-phase-ii-clarinet-forte-results-show-increasing-dose-frequencies-of-somatuline-autogel-lanreotide-allows-patients-with-nets-to-delay-treatment-escalation-by-up-to-8-3-months/?s=73
https://www.globenewswire.com/news-release/2020/08/31/2086104/0/en/Chiasma-Announces-U-S-Commercial-Launch-and-Availability-of-MYCAPSSA-the-First-and-Only-Oral-Somatostatin-Analog-for-Patients-with-Acromegaly.html
http://www.pmlive.com/pharma_news/revenue_growth_at_ipsen_numbs_pain_of_palovarotene_calamity_1325622
https://www.businesswire.com/news/home/20190523005596/en/New-Investigational-Clinical-Data-Ipsen%E2%80%99s-Oncology-Products/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
http://www.businesswire.com/news/home/20170918005686/en/U.S.-FDA-Approves-New-Indication-Ipsens-Somatuline%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
http://www.drugdeliverybusiness.com/ipsen-wins-approval-gastroenteropancreatic-neuroendocrine-tumor-drug/